Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial
O’Malley S, Miranda R, Book S, Chun T, Liss T, Malcolm R, Muvvala S, Padovano H, Schacht J, Blackburn B, Diamond I, Ransom J, Ryan M, Falk D, Litten R. Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. Alcohol And Alcoholism 2025, 60: agaf001. PMID: 39829301, PMCID: PMC11744046, DOI: 10.1093/alcalc/agaf001.Peer-Reviewed Original ResearchAlcohol use disorderAldehyde dehydrogenase 2 inhibitorUse disorderTreat alcohol use disorderCue reactivity sessionsCue-elicited cravingCue-induced cravingHuman laboratory studiesTreatment-seeking adultsAlcohol use disorder pharmacotherapiesAldehyde dehydrogenase 2Multisite clinical trialDose to placeboWeeks of medicationEffect size estimatesReactivation sessionDrinking outcomesGroup differencesCravingMeasured 1 weekEffect sizeCohen's dDouble-blindPreliminary effectivenessAlcohol consumption
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply